Key takeaways
Armodafinil (Nuvigil) and methylphenidate extended-release (ER) are both prescription medications, but they serve different purposes and belong to different drug classes. Armodafinil is a wakefulness-promoting agent used to treat excessive sleepiness caused by conditions like narcolepsy, obstructive sleep apnea, and shift work disorder. On the other hand, methylphenidate ER, known by brand names like Concerta and Ritalin LA, is a stimulant primarily used to treat attention-deficit/hyperactivity disorder (ADHD). Armodafinil is a Schedule IV controlled substance, indicating a lower potential for abuse compared to methylphenidate ER, which is a Schedule II controlled substance with a higher risk for misuse and dependency. While armodafinil's exact mechanism is not well understood, it is thought to affect brain areas controlling wakefulness. Methylphenidate ER works by increasing levels of norepinephrine and dopamine in the brain, which is thought to help improve attention and focus. Both medications are taken once daily, but armodafinil is generally not recommended for children under 16, whereas methylphenidate ER can be prescribed for children as young as 6 years old. Additionally, armodafinil can interact with hormonal birth control, while methylphenidate ER is not known to have this interaction. Methylphenidate ER has a broader range of formulations, including tablets, capsules, and liquids, while armodafinil is only available as an oral tablet.
